Table 5.
Antibiotic susceptibility results of extended spectrum beta lactamase (ESBL) and non-ESBL Klebsiella pneumoniae isolates
| Antibiotic | Number of resistant isolates | |||
|---|---|---|---|---|
| Non-ESBL KP | ESBL KP | |||
| n/N | (%) | n/N | (%) | |
| Ampicillin | 71/71 | (100) | 339/339 | (100) |
| Co-amoxyclav | 5/71 | (7.1) | 280/331 | (84.6) |
| Cefotaxime | 0/71 | (0) | 339/339 | (100) |
| Ceftazidime | 0/71 | (0) | 339/339 | (100) |
| Cefepime | 0/71 | (0) | 339/339 | (100) |
| Ciprofloxacin | 0/71 | (0) | 142/339 | (41.9) |
| Cotrimoxazole | 18/71 | (25.4) | 313/339 | (92.3) |
| Amikacin | 0/71 | (0) | 98/339 | (28.9) |
| Gentamicin | 4/71 | (5.6) | 319/338 | (94.4) |
| Piperacillin-Tazobactam | 2/67 | (3.0) | 136/282 | (48.2) |
| Ertapenem | 0/67 | (0) | 2/338 | (0.6) |
| Imipenem | 0/71 | (0) | 0/338 | (0) |
| Meropenem | 0/71 | (0) | 0/338 | (0) |
KP Klebsiella pneumoniae, ESBL KPBSI Extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae bloodstream infection, co-amoxyclav amoxicillin-clavulanic acid co-formulation, n/N stratum specific proportions